Diagnostic and Prognostic Value of New Quick Tests of Action Slowing in Stroke and in Cognitive Neurodegenerative Disease
Recruiting
Observational Study
Stroke
Action Speed
Dementia Mild Cognitive Impairment
Alzheimer Disease
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 40 – 85
- Sex
- Any
- Study type
- Observational
- Participants needed
- 129 (estimated)
- Sponsor
- Centre Hospitalier Universitaire, Amiens · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
A large series of recent studies have documented the frequency of the slowing of the action in brain diseases, especially vascular and neurodegenerative diseases. In stroke, the predictive value of action slowing at the acute phase for predicting post-stroke functional outcome remains poorly investigated. In neurodegenerative diseases, the diagnostic relevance of the slowing at the prodromal stage…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Patients between 40 and 85 years old,
* French native language,
* Social Security affiliation.
* University Memory Clinic for: Mild severity disorder (MMSE\> 19) or major severity disorder related to AD : Albert 2011 criteria ; McKhann 2011
* to MCL according to McKeith criter…
Contacts